-
-
-
-
-
-
-
FDA approves Revolution Medicines pancreatic cancer drug Rasonque
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Revolution (RVMD)
-
-
-
-
-
-
-
Revolution (RVMD) trading up 1%, RBC says that's about what they expected it to trade
-
-
-
-
-
-
-
Revolution Medicines schedules call on pancreatic cancer trial results
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $186 at Needham
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $165 at Oppenheimer
-
-
-
-
-
-
-
Revolution Medicines (RVMD) call put ratio 1 call to 4.7 puts with a focus on April 70 and 90 puts
-
456,295 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

